{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T16:03:29Z","timestamp":1772381009528,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is a multisystem syndrome associated with significant morbidity and mortality, particularly kidney failure. This study sought to evaluate mortality and transplant outcomes in Australian and New Zealand patients with ADPKD commencing kidney replacement therapy (KRT).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A retrospective review of all patients with kidney failure over 18 years of age commencing KRT between 1963 and 2020, stratified across eras, using Australia and New Zealand Transplant (ANZDATA) Registry data. People with ADPKD were compared to those with other causes of kidney failure (non-ADPKD). The primary outcome was mortality on dialysis. Secondary outcomes included post-kidney transplant patient survival and graft survival (both death-censored and with death as a competing risk). Outcomes were compared using multivariable Cox proportional hazards models.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>During the study period, 63,875 patients commenced KRT, including 2,466 (3.9%) with ADPKD. Compared to patients without ADPKD, those with ADPKD had generally fewer comorbidities at KRT initiation. ADPKD was independently associated with a lower risk of mortality on dialysis (adjusted hazard ratio [aHR], 0.71, 95% CI 0.67\u20130.75, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Causes of death were similar between the ADPKD and non-ADPKD cohorts including for cardiovascular disease (27.5% vs. 27.6%, respectively), infection (7.9% vs. 8.5%) and cancer (3.4% vs. 3.5%). Kidney transplant recipients had fewer comorbidities across both cohorts, with a similar incidence of coronary artery disease (ADPKD 7.2% vs. non-ADPKD 8.0%). Compared with non-ADPKD, ADPKD was associated with a similar mortality risk in kidney transplant recipients (aHR, 0.96, 95% CI 0.88\u20131.05) and slightly improved graft survival (aHR, 0.87; 95% CI 0.77\u20130.97, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05), although there was no difference in death-censored graft survival (aHR, 0.92, 95% CI 0.79\u20131.07).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Compared to other causes of kidney failure, ADPKD is associated with better patient survival on dialysis, similar patient survival post-kidney transplantation and similar death-censored graft survival.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12882-025-04185-1","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:21:09Z","timestamp":1759155669000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of autosomal dominant polycystic kidney disease (ADPKD) with cardiovascular disease and mortality in patients with treated kidney failure"],"prefix":"10.1186","volume":"26","author":[{"given":"Julia","family":"Jefferis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Mallett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gopi","family":"Rangan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeoungjee","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea K.","family":"Viecelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkat","family":"Vangaveti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmel M.","family":"Hawley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"4185_CR1","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1750-1172-9-98","volume":"9","author":"A Mallett","year":"2014","unstructured":"Mallett A, Patel C, Salisbury A, Wang Z, Healy H, Hoy W. The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia. Orphanet J Rare Dis. 2014;9:98.","journal-title":"Orphanet J Rare Dis"},{"key":"4185_CR2","volume-title":"Welfare. Chronic kidney disease: Australian facts","author":"Health","year":"2024","unstructured":"Health, AIo. Welfare. Chronic kidney disease: Australian facts. Canberra: AIHW; 2024."},{"key":"4185_CR3","volume-title":"Welfare. Heart, stroke and vascular disease: Australian facts","author":"Health","year":"2024","unstructured":"Health, AIo. Welfare. Heart, stroke and vascular disease: Australian facts. Canberra: AIHW; 2024."},{"key":"4185_CR4","unstructured":"Irish G, Au CDE, Bateman S, Chen J, Hurst K, Kholmurodova F, Lee D, McCarthy H, McDonald, S, Mulley W, Solomon MRB, Sun T. P Clayton. Chapter 1: Incidence of kidney failure with replacement therapy. Australia and New Zealand Dialysis and Transplant Registry. ANZDATA, 2024. Available at: http:\/\/www.anzdata.org.au."},{"issue":"4","key":"4185_CR5","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1053\/j.ajkd.2017.01.046","volume":"70","author":"E Cornec-Le Gall","year":"2017","unstructured":"Cornec-Le Gall E, Audr\u00e9zet M-P, Renaudineau E, Hourmant M, Charasse C, Michez E, et al. PKD2-Related autosomal dominant polycystic kidney disease: prevalence, clinical presentation, mutation spectrum, and prognosis. Am J Kidney Diseases: Official J Natl Kidney Foundation. 2017;70(4):476\u201385.","journal-title":"Am J Kidney Diseases: Official J Natl Kidney Foundation"},{"issue":"5","key":"4185_CR6","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/ki.1992.195","volume":"41","author":"PA Gabow","year":"1992","unstructured":"Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, Jones RH. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int. 1992;41(5):1311\u20139.","journal-title":"Kidney Int"},{"issue":"10","key":"4185_CR7","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1681\/ASN.V8101560","volume":"8","author":"AM Johnson","year":"1997","unstructured":"Johnson AM, Gabow PA. Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol. 1997;8(10):1560\u20137.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"4185_CR8","doi-asserted-by":"publisher","first-page":"710","DOI":"10.2215\/CJN.01581105","volume":"1","author":"E Dicks","year":"2006","unstructured":"Dicks E, Ravani P, Langman D, Davidson WS, Pei Y, Parfrey PS. Incident renal events and risk factors in autosomal dominant polycystic kidney disease: A population and Family-Based cohort followed for 22 years. Clin J Am Soc Nephrol. 2006;1(4):710.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"4185_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12963-017-0123-7","volume":"15","author":"MR Fernando","year":"2017","unstructured":"Fernando MR, Dent H, McDonald SP, Rangan GK. Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and new Zealand (1963\u20132014). Popul Health Metrics. 2017;15(1):7.","journal-title":"Popul Health Metrics"},{"issue":"5","key":"4185_CR10","first-page":"806","volume":"20","author":"E Rahman","year":"2009","unstructured":"Rahman E, Niaz FA, Al-Suwaida A, Nahrir S, Bashir M, Rahman H, Hammad D. Analysis of causes of mortality in patients with autosomal dominant polycystic kidney disease: a single center study. Saudi J Kidney Dis Transpl. 2009;20(5):806\u201310.","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"10","key":"4185_CR11","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.2215\/CJN.01750309","volume":"4","author":"DW Johnson","year":"2009","unstructured":"Johnson DW, Dent H, Hawley CM, McDonald SP, Rosman JB, Brown FG, et al. Association of dialysis modality and cardiovascular mortality in incident dialysis patients. Clin J Am Soc Nephrol. 2009;4(10):1620\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"4185_CR12","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/nep.13566","volume":"24","author":"Y Cho","year":"2019","unstructured":"Cho Y, Sautenet B, Gutman T, Rangan G, Craig JC, Ong AC, et al. Identifying patient-important outcomes in polycystic kidney disease: an international nominal group technique study. Nephrol (Carlton). 2019;24(12):1214\u201324.","journal-title":"Nephrol (Carlton)"},{"key":"4185_CR13","doi-asserted-by":"crossref","unstructured":"Lee LJ-H, Tsai L-K, Chang Y-Y, Wang J-D, Kao JT-W. Incidence of stroke among patients with polycystic kidney disease in Taiwan: A retrospective population-based cohort study using National health insurance database. Biomedical J. 2021;45(5):806\u201313.","DOI":"10.1016\/j.bj.2021.10.005"},{"issue":"1","key":"4185_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1471-2369-15-39","volume":"15","author":"DJ Yoo","year":"2014","unstructured":"Yoo DJ, Agodoa L, Yuan CM, Abbott KC, Nee R. Risk of intracranial hemorrhage associated with autosomal dominant polycystic kidney disease in patients with end stage renal disease. BMC Nephrol. 2014;15(1):39.","journal-title":"BMC Nephrol"},{"issue":"4","key":"4185_CR15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1053\/ajkd.2001.27720","volume":"38","author":"RD Perrone","year":"2001","unstructured":"Perrone RD, Ruthazer R, Terrin NC. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am J Kidney Dis. 2001;38(4):777\u201384.","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 4","key":"4185_CR16","doi-asserted-by":"publisher","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","volume":"29","author":"EM Spithoven","year":"2014","unstructured":"Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Abad JM, et al. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival\u2013an analysis of data from the ERA-EDTA registry. Nephrol Dial Transpl. 2014;29(Suppl 4):iv15\u201325.","journal-title":"Nephrol Dial Transpl"},{"key":"4185_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/1471-2369-14-186","volume":"14","author":"V Mart\u00ednez","year":"2013","unstructured":"Mart\u00ednez V, Comas J, Arcos E, D\u00edaz JM, Muray S, Cabezuelo J, et al. Renal replacement therapy in ADPKD patients: a 25-year survey based on the Catalan registry. BMC Nephrol. 2013;14:186.","journal-title":"BMC Nephrol"},{"issue":"11","key":"4185_CR18","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1093\/ndt\/gfx364","volume":"33","author":"M Sigogne","year":"2018","unstructured":"Sigogne M, Kanagaratnam L, Dupont V, Couchoud C, Verger C, Maheut H, et al. Outcome of autosomal dominant polycystic kidney disease patients on peritoneal dialysis: a National retrospective study based on two French registries (the French Language peritoneal Dialysis registry and the French renal epidemiology and information Network). Nephrol Dial Transpl. 2018;33(11):2020\u20136.","journal-title":"Nephrol Dial Transpl"},{"issue":"10","key":"4185_CR19","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.2215\/cjn.01750309","volume":"4","author":"DW Johnson","year":"2009","unstructured":"Johnson DW, Dent H, Hawley CM, McDonald SP, Rosman JB, Brown FG, et al. Association of dialysis modality and cardiovascular mortality in incident dialysis patients. Clin J Am Soc Nephrol. 2009;4(10):1620\u20138. https:\/\/doi.org\/10.2215\/cjn.01750309. Epub 2009\/09\/05.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"4185_CR20","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/S0272-6386(97)90276-6","volume":"30","author":"SSA Fenton","year":"1997","unstructured":"Fenton SSA, Schaubel DE, Desmeules M, Morrison HI, Mao Y, Copleston P, et al. Hemodialysis versus peritoneal dialysis: A comparison of adjusted mortality rates. Am J Kidney Dis. 1997;30(3):334\u201342. https:\/\/doi.org\/10.1016\/S0272-6386(97)90276-6.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"4185_CR21","doi-asserted-by":"publisher","first-page":"e14418","DOI":"10.1111\/nep.14418","volume":"30","author":"JY Lee","year":"2025","unstructured":"Lee JY, Cho H, Park JH, Jo YI. Comparison of survival outcomes in haemodialysis versus immediate-start peritoneal dialysis: A propensity-matched study. Nephrol (Carlton). 2025;30(1):e14418. https:\/\/doi.org\/10.1111\/nep.14418. PubMed PMID: 39675379.","journal-title":"Nephrol (Carlton)"},{"issue":"1","key":"4185_CR22","doi-asserted-by":"publisher","first-page":"6746","DOI":"10.1038\/s41598-024-57273-x","volume":"14","author":"HY Han","year":"2024","unstructured":"Han HY, Vangaveti V, Jose M, Ng MSY, Mallett AJ. People with genetic kidney diseases on kidney replacement therapy have different clinical outcomes compared to people with other kidney diseases. Sci Rep. 2024;14(1):6746.","journal-title":"Sci Rep"},{"key":"4185_CR23","volume-title":"P Clayton. 46th report, chap. 3: mortality in kidney failure with replacement therapy","author":"E Au","year":"2023","unstructured":"Au E, Bateman S, Chen J, Hurst K, Irish G, Lee D, et al. 46th report, Chapter 3: Mortality in kidney failure with replacement therapy. Adelaide (AU): Australia and New Zealand Dialysis and Transplant Registry; 2023."},{"issue":"8","key":"4185_CR24","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.2215\/CJN.02100219","volume":"14","author":"A Flahault","year":"2019","unstructured":"Flahault A, Joly D. Screening for intracranial aneurysms in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2019;14(8):1242\u20134.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"4185_CR25","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1681\/ASN.V5122048","volume":"5","author":"GM Fick","year":"1995","unstructured":"Fick GM, Johnson AM, Hammond WS, Gabow PA. Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1995;5(12):2048\u201356.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"4185_CR26","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/0002-9343(87)90005-2","volume":"82","author":"SJ Schwab","year":"1987","unstructured":"Schwab SJ, Bander SJ, Klahr S. Renal infection in autosomal dominant polycystic kidney disease. Am J Med. 1987;82(4):714\u20138.","journal-title":"Am J Med"},{"issue":"10","key":"4185_CR27","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.ekir.2023.07.017","volume":"8","author":"PS Sagar","year":"2023","unstructured":"Sagar PS, Rangan GK. Cardiovascular manifestations and management in ADPKD. Kidney Int Rep. 2023;8(10):1924\u201340.","journal-title":"Kidney Int Rep"},{"issue":"6","key":"4185_CR28","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1053\/j.ajkd.2011.01.023","volume":"57","author":"C Patch","year":"2011","unstructured":"Patch C, Charlton J, Roderick PJ, Gulliford MC. Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Am J Kidney Dis. 2011;57(6):856\u201362. https:\/\/doi.org\/10.1053\/j.ajkd.2011.01.023. Epub 20110402.","journal-title":"Am J Kidney Dis"},{"key":"4185_CR29","doi-asserted-by":"publisher","unstructured":"Aung TT, Bhandari SK, Chen Q, Malik FT, Willey CJ, Reynolds K et al. Autosomal dominant polycystic kidney disease prevalence among a racially diverse United States population, 2002 through 2018. Kidney360. 2021. https:\/\/doi.org\/10.34067\/KID.0004522021.","DOI":"10.34067\/KID.0004522021"},{"key":"4185_CR30","doi-asserted-by":"publisher","unstructured":"St Pierre K, Cashmore BA, Bolignano D, Zoccali C, Ruospo M, Craig JC et al. Interventions for preventing the progression of autosomal dominant polycystic kidney disease. Cochrane Database Syst Rev. 2024;10(10):Cd010294. Epub 20241002. https:\/\/doi.org\/10.1002\/14651858.CD010294.pub3. PubMed PMID: 39356039; PubMed Central PMCID: PMC11445802.","DOI":"10.1002\/14651858.CD010294.pub3"},{"issue":"1","key":"4185_CR31","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12882-017-0641-3","volume":"18","author":"W-C Tran","year":"2017","unstructured":"Tran W-C, Huynh D, Chan T, Chesla CA, Park M. Understanding barriers to medication, dietary, and lifestyle treatments prescribed in polycystic kidney disease. BMC Nephrol. 2017;18(1):214.","journal-title":"BMC Nephrol"},{"issue":"6","key":"4185_CR32","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/j.1432-2277.2011.01237.x","volume":"24","author":"A Jacquet","year":"2011","unstructured":"Jacquet A, Pallet N, Kessler M, Hourmant M, Garrigue V, Rostaing L, et al. Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study. Transpl Int. 2011;24(6):582\u20137.","journal-title":"Transpl Int"},{"issue":"7","key":"4185_CR33","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1093\/ndt\/12.7.1431","volume":"12","author":"H Hadimeri","year":"1997","unstructured":"Hadimeri H, Nord\u00e9n G, Friman S, Nyberg G. Autosomal dominant polycystic kidney disease in a kidney transplant population. Nephrol Dial Transpl. 1997;12(7):1431\u20136.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"4185_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5414\/CNP58016","volume":"58","author":"B Stiasny","year":"2002","unstructured":"Stiasny B, Ziebell D, Graf S, Hauser IA, Schulze BD. Clinical aspects of renal transplantation in polycystic kidney disease. Clin Nephrol. 2002;58(1):16\u201324.","journal-title":"Clin Nephrol"},{"issue":"2","key":"4185_CR35","doi-asserted-by":"publisher","first-page":"312","DOI":"10.34067\/KID.0001182019","volume":"2","author":"G Bhutani","year":"2021","unstructured":"Bhutani G, Astor BC, Mandelbrot DA, Mankowski-Gettle L, Ziemlewicz T, Wells SA, et al. Long-Term outcomes and prognostic factors in kidney transplant recipients with polycystic kidney disease. Kidney360. 2021;2(2):312\u201324.","journal-title":"Kidney360"},{"issue":"9","key":"4185_CR36","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/j.ekir.2022.06.006","volume":"7","author":"M Chedid","year":"2022","unstructured":"Chedid M, Kaidbay H-D, Wigerinck S, Mkhaimer Y, Smith B, Zubidat D, et al. Cardiovascular outcomes in kidney transplant recipients with ADPKD. Kidney Int Rep. 2022;7(9):1991\u20132005.","journal-title":"Kidney Int Rep"},{"key":"4185_CR37","doi-asserted-by":"crossref","unstructured":"Tsai TY, Chen CH, Wu MJ, Tsai SF. Outcomes of kidney transplantation in patients with autosomal dominant polycystic kidney disease: our experience based on 35-Years Follow-Up. Diagnostics (Basel). 2022;12(5).","DOI":"10.3390\/diagnostics12051174"},{"issue":"5","key":"4185_CR38","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1097\/TXD.0000000000000989","volume":"6","author":"A Culliford","year":"2020","unstructured":"Culliford A, Phagura N, Sharif A. Autosomal dominant polycystic kidney disease is a risk factor for posttransplantation diabetes mellitus: an updated systematic review and Meta-analysis. Transpl Direct. 2020;6(5):e553.","journal-title":"Transpl Direct"},{"issue":"4","key":"4185_CR39","first-page":"538","volume":"40","author":"Q Li","year":"2020","unstructured":"Li Q, Li J, Yang F, Liu Y, Deng W, Liu R, et al. [Application of immunosuppressants in patients with autosomal dominant polycystic kidney disease after kidney transplantation]. Nan Fang Yi Ke Da Xue Xue Bao. 2020;40(4):538\u201343.","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"issue":"8","key":"4185_CR40","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/nep.12658","volume":"21","author":"GK Rangan","year":"2016","unstructured":"Rangan GK, Alexander SI, Campbell KL, Dexter MA, Lee VW, Lopez-Vargas P, et al. KHA-CARI guideline recommendations for the diagnosis and management of autosomal dominant polycystic kidney disease. Nephrology. 2016;21(8):705\u201316.","journal-title":"Nephrology"},{"issue":"803","key":"4185_CR41","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1136\/pgmj.68.803.735","volume":"68","author":"M Rivera","year":"1992","unstructured":"Rivera M, Gonzalo A, Gobernado JM, Orte L, Quereda C, Ortu\u00f1o J. Stroke in adult polycystic kidney disease. Postgrad Med J. 1992;68(803):735\u20138.","journal-title":"Postgrad Med J"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04185-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04185-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04185-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:21:11Z","timestamp":1759155671000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04185-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4185"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04185-1","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Collection and analysis of ANZDATA registry data was approved by the Metro South Ethics Human Research and Ethics Committee (HREC\/2022\/QMS\/84918).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"is not applicable for this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"542"}}